YWYuanhang Wang

Yuanhang Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yuanhang Wang has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Ping Lu

    Department of Oncology The First Affiliated Hospital of Xinxiang Medical University Weihui China

    2 shared publications
  • Houyu Zhao

    Department of Oncology, The First Affiliated Hospital of Xinxiang Medical University, Weihui, China

    1 shared publication
  • Jinghang Zhang

    Department of Pathology The First Affiliated Hospital of Xinxiang Medical University Weihui China

    1 shared publication
  • Jingjing Zhang

    Department of Oncology The First Affiliated Hospital of Xinxiang Medical University Weihui China

    1 shared publication
  • Kelei Zhao

    Department of Oncology The First Affiliated Hospital of Xinxiang Medical University Weihui China

    1 shared publication
  • Min Zhang

    Department of Oncology, The First Affiliated Hospital of Xinxiang Medical University, Weihui, China

    1 shared publication

Latest Publications

  • Open Access

    Rapid Response to Penpulimab Combined With Anlotinib and Chemotherapy in a Thoracic SMARCA4‐UT Without PD‐L1 Expression: A Case Report and Review of Literature

    by Yuanhang Wang, Kelei Zhao, Jingjing Zhang, Xiaohan Yuan, Yanting Liu, Jinghang Zhang, Ping Lu, Min Zhang

    SMARCA4‐deficient undifferentiated tumor (SMARCA4‐UT) in the chest is a high‐grade malignant tumor that grows rapidly and often carries a poor prognosis. Unfortunately, there are currently no effective treatment available until now. Here, we report a case of SMARCA4‐UT in a patient who showed a swift response to a combination treatment of penpulimab, anlotinib, and chemotherapy. A 55‐year‐old man was diagnosed with thoracic SMARCA4‐UT along with metastases to multiple lymph nodes, the pleura, and bones. Immunohistochemical (IHC) testing indicated the absence of PD‐L1 expression in tumor cells. He was given sintilimab and anlotinib as first line treatment. However, a follow‐up chest CT revealed progressive disease (PD) after the first cycle treatment. Subsequently, the second line regimen was modified to etoposide and cisplatin (EP) combined with anlotinib and penpulimab. The effectiveness evaluation revealed partial remission (PR) following two cycles of the second‐line regimen treatment. Notably, the patient's progress‐free survival (PFS) exceeds 7 months and the overall survival up to 12 months. Our case implies that a combination of chemotherapy, anlotinib, and penpulimab might offer a promising therapeutic approach for PD‐L1‐negative thoracic SMARCA4‐UT.


  • Open Access

    Recent Progress of Bioinspired Cell Membrane in Cancer Immunotherapy

    by Min Zhang, Yuanhang Wang, Zhiyuan Song, Yimeng Lu, Houyu Zhao, Yihan Wang, Ping Lu, Yanting Liu

    By modifying immune cells, immunotherapy can activate immune response to establish long-term immune memory and prevent tumor recurrence. However, their effectiveness is largely constricted by the poor immunogenicity, immune escape, and immune tolerance of the tumor. This is related to the characteristics of the tumor itself, such as genome instability and mutation. The combination of various nanocarriers with tumor immunotherapy is beneficial for overcoming the shortcomings of traditional immunotherapy. Nanocarriers coated by cell membranes can extend blood circulation time, improve ability to evade immune clearance, and enhance targeting, thus significantly enhancing the efficacy of immunotherapy and showing great potential in tumor immunotherapy. This article reviews the application research progress of different types of cell membrane–modified nanocarriers in tumor immunotherapy, immunotherapy combination therapy, and tumor vaccines, and provides prospects for future research.